Thursday, September 26, 2019 5:47:55 PM
I think that based on the market most would agree that there might be better compounds or MOA's
STILL...Luly did seem to reiterate that he believed in FXR. I'll have to listen again.
I'm not saying that Luly doubled down on the higher dose 2.5mg (I really thought it was out of the picture), but he also seemed to be interested in higher dose (what if it were 2.mg?) for heavier lifting, but also the lower dose (1. or .75mg hypothetically) for a longer term or with coupled with a 2nd partnered agent.
The words he said made me think they would go ahead; but middle of next year gives one pause; not like we are starting enrollment next week. : )
So far as "surprise"; if you have about a 50% discontinuation rate at 2.5 and even a 2% discontinuation rate at 1.mg, some element is not a surprise; but yes, perhaps a surprise you've known about for a while.
Here's the thing.
When Vertex started phase 2a trials in what would become Telaprevir/Incivek caused severe rash- SJS (Stevens-Johnson syndrome). I met a guy in a trial that showed up in the ER, and it scared the hell out of the staff; like initial reaction as if the guy had ebola. : )
In time it became something that they would anticipate, and "try to stay ahead of". Same happened w/ simeprevir. This a a far more mild rash, and when people understand it won't kill them they may be less likely to drop out. Even doctors can get spooked. Rates can change when people know it's safer than their fears.
There may be ways to augment or modify TX where they can improve response without throwing out the compound.
(which is why other trials continue, subpar as they may be)
AND.... what if one of ENTA's other follow on compounds could be partnered? Luly and ENTA know a lot more about their cards than investors. They may even also know something about the other cards in other players hands.
I realize I'm spinning this to be positive on a down day. I may not be as far along as you are on wanting them to stop. Their best judgement is far better than mine. : )
Recent ENTA News
- Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 • Business Wire • 04/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:27:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:19:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:15:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:12:41 PM
- Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference • Business Wire • 03/06/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:31:52 PM
- Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/27/2024 06:11:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:23:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:21:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:18:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:15:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:12:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:09:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:00:28 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:26:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:24:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:05:12 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET • Business Wire • 02/07/2024 09:01:00 PM
- Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • Business Wire • 02/06/2024 12:00:00 PM
- Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023 • Business Wire • 01/31/2024 12:00:00 PM
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM